Compare Stocks: ALXO, LXRX, JBIO, and FBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.96 +1.0%	$1.91	$0.62 ▼ $2.66	$268.26M	0.42	1.07 million shs	584,061 shs
FBRX Forte Biosciences	$76.83 0.0%	$43.25	$10.11 ▼ $77.20	$1.07B	2.62	2.27 million shs	490,179 shs
JBIO Jade Biosciences	$24.71 +3.8%	$20.23	$6.67 ▼ $28.00	$1.51B	1.49	803,573 shs	1.48 million shs
LXRX Lexicon Pharmaceuticals	$2.32 -0.9%	$2.25	$1.03 ▼ $2.68	$1.04B	1.08	2.89 million shs	1.76 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+1.03%	-6.67%	-3.45%	-3.45%	+196.70%
FBRX Forte Biosciences	-0.04%	+0.05%	+74.02%	+232.45%	+626.87%
JBIO Jade Biosciences	+3.78%	+12.52%	+13.04%	+5.82%	+237.11%
LXRX Lexicon Pharmaceuticals	-0.85%	-6.07%	+5.45%	+4.04%	+109.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.96 +1.0%	$1.91	$0.62 ▼ $2.66	$268.26M	0.42	1.07 million shs	584,061 shs
FBRX Forte Biosciences	$76.83 0.0%	$43.25	$10.11 ▼ $77.20	$1.07B	2.62	2.27 million shs	490,179 shs
JBIO Jade Biosciences	$24.71 +3.8%	$20.23	$6.67 ▼ $28.00	$1.51B	1.49	803,573 shs	1.48 million shs
LXRX Lexicon Pharmaceuticals	$2.32 -0.9%	$2.25	$1.03 ▼ $2.68	$1.04B	1.08	2.89 million shs	1.76 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+1.03%	-6.67%	-3.45%	-3.45%	+196.70%
FBRX Forte Biosciences	-0.04%	+0.05%	+74.02%	+232.45%	+626.87%
JBIO Jade Biosciences	+3.78%	+12.52%	+13.04%	+5.82%	+237.11%
LXRX Lexicon Pharmaceuticals	-0.85%	-6.07%	+5.45%	+4.04%	+109.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	134.69% Upside
FBRX Forte Biosciences	2.14	Hold	$72.50	-5.64% Downside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.75	109.43% Upside
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	96.12% Upside

Current Analyst Ratings Breakdown

Latest ALXO, LXRX, JBIO, and FBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/10/2026	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$45.00 ➝ $47.00
8/10/2026	JBIO Jade Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$74.00 ➝ $77.00
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00
7/27/2026	FBRX Forte Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.98 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$13.24 per share	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.92 per share	N/A
LXRX Lexicon Pharmaceuticals	$49.80M	20.73	N/A	N/A	$0.39 per share	5.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	N/A
FBRX Forte Biosciences	-$69.38M	-$4.64	N/A	N/A	N/A	N/A	-94.82%	-77.68%	N/A
JBIO Jade Biosciences	-$127.41M	-$1.92	N/A	N/A	N/A	N/A	-49.11%	-45.62%	N/A
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	N/A

Latest ALXO, LXRX, JBIO, and FBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/10/2026	Q2 2026	JBIO Jade Biosciences	-$0.66	-$0.76	-$0.10	-$0.76	N/A	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
FBRX Forte Biosciences	N/A	10.01	2.75
JBIO Jade Biosciences	N/A	14.93	14.29
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
FBRX Forte Biosciences	77.63%
JBIO Jade Biosciences	N/A
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
FBRX Forte Biosciences	4.40%
JBIO Jade Biosciences	23.06%
LXRX Lexicon Pharmaceuticals	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
FBRX Forte Biosciences	5	13.89 million	13.28 million	Optionable
JBIO Jade Biosciences	20	63.60 million	48.93 million	N/A
LXRX Lexicon Pharmaceuticals	140	444.96 million	382.66 million	Optionable

ALXO, LXRX, JBIO, and FBRX Headlines

Recent News About These Companies

Lexicon (LXRX) Q2 2026 Earnings Call Transcript

August 13 at 3:27 PM | finance.yahoo.com

Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 10, 2026 | seekingalpha.com

Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX

August 10, 2026 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for LXRX Earnings

August 10, 2026 | americanbankingnews.com

HC Wainwright Issues Positive Forecast for LXRX Earnings

August 10, 2026 | marketbeat.com

Wall Street Zen Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Sell

August 8, 2026 | americanbankingnews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen

August 8, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS

August 7, 2026 | marketbeat.com

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2026 | zacks.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings

August 6, 2026 | marketbeat.com

Lexicon: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission

August 6, 2026 | quiverquant.comQ

Lexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updates

August 6, 2026 | quiverquant.comQ

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

August 6, 2026 | globenewswire.com

Lexicon Pharmaceuticals Q2 2026 earnings preview

August 5, 2026 | msn.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Zacks Research

August 5, 2026 | marketbeat.com

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026 | globenewswire.com

Lexicon Pharmaceuticals (LXRX) As Phase 3 Enrollment Beats Plan Faces An Undervalued View

July 30, 2026 | finance.yahoo.com

750,000 Shares in Lexicon Pharmaceuticals, Inc. $LXRX Purchased by ADAR1 Capital Management LLC

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO, LXRX, JBIO, and FBRX Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.96 +0.02 (+1.03%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.94 -0.02 (-0.97%)

As of 08/14/2026 07:34 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Forte Biosciences NASDAQ:FBRX

$76.83 -0.03 (-0.04%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.85 +0.02 (+0.03%)

As of 08/14/2026 07:34 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Jade Biosciences NASDAQ:JBIO

$24.71 +0.90 (+3.78%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$24.72 +0.00 (+0.02%)

As of 08/14/2026 07:34 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.32 -0.02 (-0.85%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+0.65%)

As of 08/14/2026 07:34 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALXO, LXRX, JBIO, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALXO, LXRX, JBIO, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALXO, LXRX, JBIO, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO, LXRX, JBIO, and FBRX Company Descriptions

ALX Oncology NASDAQ:ALXO

Forte Biosciences NASDAQ:FBRX

Jade Biosciences NASDAQ:JBIO

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALXO, LXRX, JBIO, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALXO, LXRX, JBIO, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALXO, LXRX, JBIO, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO, LXRX, JBIO, and FBRX Company Descriptions

ALX Oncology NASDAQ:ALXO

Forte Biosciences NASDAQ:FBRX

Jade Biosciences NASDAQ:JBIO

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools